A Phase 1, Open-label, Randomized, Crossover Study Evaluating the Bioavailability of TAS-102 Tablets Relative to an Oral Solution Containing Equivalent Amounts of FTD and TPI
Phase of Trial: Phase I
Latest Information Update: 09 Jan 2017
At a glance
- Drugs Tipiracil/trifluridine (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Taiho Pharmaceutical
- 09 Jan 2017 Results of this bioavailability study and it's extension part published in the Journal of Clinical Pharmacology.
- 22 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.